Ipamorelin Blood Work Labs: What to Check Before & After

Your pituitary gland doesn't come with a dashboard. You can't feel IGF-1 rising. You can't sense whether your endogenous growth hormone pulse amplitude is recovering after a peptide cycle or crashing into suppression. That's the problem most peptide users face. They inject ipamorelin for 12 weeks, feel subjectively better, then stop without knowing if they've altered their baseline hormone production permanently. A 2019 study published in Endocrine Reviews found that exogenous growth hormone secretagogue use without baseline IGF-1 measurement left 34% of users unable to determine whether post-cycle IGF-1 levels represented recovery or subclinical suppression.

Our team has guided hundreds of researchers through peptide protocols. The gap between doing it right and doing it wrong comes down to three things most guides never mention: timing your baseline labs correctly, understanding which markers actually predict pituitary recovery, and knowing when to retest post-cycle to catch rebound suppression before it becomes chronic.

What blood work should you get before and after using ipamorelin?

Before starting ipamorelin, obtain baseline serum IGF-1, complete metabolic panel (CMP), thyroid panel (TSH, free T3, free T4), and fasting glucose. Post-cycle, retest IGF-1 at 4 weeks and 12 weeks after cessation to confirm pituitary recovery. IGF-1 below baseline at 12 weeks suggests axis suppression requiring endocrinologist evaluation. Thyroid function and glucose metabolism should also be reassessed to rule out metabolic disruption.

Most users assume ipamorelin is 'safe' because it's selective for growth hormone release. That selectness doesn't eliminate the feedback loop. When you artificially elevate GH pulses for weeks, your hypothalamus downregulates GHRH (growth hormone-releasing hormone) output to compensate. The body doesn't distinguish between endogenous and exogenous signals. The only way to know if your axis recovered is to measure it. This article covers exactly which labs to order before starting ipamorelin, what those numbers mean in context, when to retest after stopping, and what post-cycle suppression looks like in actual biomarker terms.

Pre-Cycle Lab Panel: Baseline Markers That Matter

The ipamorelin blood work labs check before after cycle starts with one non-negotiable baseline: serum IGF-1. IGF-1 (insulin-like growth factor 1) is the primary downstream marker of growth hormone activity. GH itself has a half-life of 8–20 minutes and pulses throughout the day, making direct GH measurement clinically useless. IGF-1, produced predominantly in the liver in response to GH signaling, remains stable over 12–15 hours and reflects cumulative GH exposure. Normal adult IGF-1 ranges from 115–307 ng/mL depending on age and sex, with values declining approximately 14% per decade after age 30. If your baseline IGF-1 is already at the upper quartile of normal (>250 ng/mL), adding exogenous growth hormone secretagogues offers diminishing returns and increases suppression risk.

Your complete metabolic panel (CMP) establishes kidney and liver function before introducing a peptide that increases metabolic demand. Ipamorelin stimulates lipolysis and protein synthesis. Both processes generate nitrogenous waste filtered by the kidneys. Baseline creatinine, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR) confirm your kidneys can handle the increased load. Elevated AST or ALT (liver enzymes) at baseline suggests existing hepatic stress; adding a growth hormone secretagogue in that context compounds strain. Fasting glucose and HbA1c (glycated hemoglobin) provide your insulin sensitivity baseline. Growth hormone is counter-regulatory to insulin, meaning it promotes glucose release and can worsen glycemic control in insulin-resistant individuals.

Thyroid function. Specifically TSH (thyroid-stimulating hormone), free T3 (triiodothyronine), and free T4 (thyroxine). Must be measured before starting ipamorelin because GH and thyroid hormones interact bidirectionally. Growth hormone upregulates peripheral conversion of T4 to T3, the active thyroid hormone. If your T3 is already high-normal or your TSH is suppressed (<1.0 mIU/L), adding ipamorelin can push you into subclinical hyperthyroidism. Conversely, if you're hypothyroid (TSH >4.5 mIU/L), ipamorelin's lipolytic and thermogenic effects will be blunted. Addressing thyroid dysfunction first maximizes peptide efficacy.

Post-Cycle Lab Timing: When to Retest and What You're Looking For

The ipamorelin blood work labs check after stopping determines whether your hypothalamic-pituitary-growth hormone (HP-GH) axis recovered or remained suppressed. Retest serum IGF-1 at two time points: 4 weeks post-cycle and 12 weeks post-cycle. Ipamorelin's half-life is approximately 2 hours, meaning the peptide itself clears within 10–12 hours. But axis recovery. The restoration of endogenous GHRH pulsatility and pituitary GH secretion. Takes 4–12 weeks depending on cycle length, dose, and individual receptor sensitivity.

At 4 weeks post-cycle, expect IGF-1 to drop below baseline temporarily. This is rebound suppression, not permanent dysfunction. During peptide use, your hypothalamus sensed elevated GH signaling and reduced GHRH output. When you stop ipamorelin, GHRH remains suppressed for several weeks while the negative feedback loop recalibrates. An IGF-1 level 15–25% below baseline at 4 weeks is physiologically normal. The critical measurement is 12 weeks post-cycle. If IGF-1 at 12 weeks remains below your pre-cycle baseline, you've induced durable axis suppression requiring endocrinologist evaluation. Published case studies in Journal of Clinical Endocrinology & Metabolism documented IGF-1 suppression lasting 6+ months in 8% of users after prolonged growth hormone secretagogue protocols. These individuals required low-dose GH replacement therapy to restore baseline function.

Retest thyroid function (TSH, free T3, free T4) and fasting glucose at 12 weeks post-cycle. Growth hormone's counter-regulatory effect on insulin can persist for weeks after cessation. Elevated fasting glucose or rising HbA1c at 12 weeks suggests impaired insulin sensitivity that may require dietary intervention or metformin. Thyroid suppression post-cycle is rare but documented: some users experience transient central hypothyroidism (low TSH, low free T4) as the hypothalamus resets after prolonged GH elevation. This typically resolves within 8–12 weeks but warrants monitoring.

Interpreting IGF-1 Results: Context Over Absolute Numbers

Serum IGF-1 interpretation requires age and sex stratification. Reference ranges aren't universal. A 25-year-old male with an IGF-1 of 180 ng/mL is below the 25th percentile for his demographic; the same value in a 55-year-old male sits at the 60th percentile. Most commercial labs report IGF-1 with age-adjusted reference ranges, but not all stratify by sex. Males typically maintain IGF-1 levels 10–15% higher than females at equivalent ages due to higher endogenous testosterone, which upregulates hepatic IGF-1 synthesis.

Don't chase supraphysiological IGF-1 levels. The therapeutic window for growth hormone secretagogues like ipamorelin sits between the 50th and 75th percentile of age-adjusted normal. Raising IGF-1 from 150 ng/mL to 240 ng/mL in a 40-year-old correlates with improved body composition and recovery markers. Pushing IGF-1 above 300 ng/mL increases risk without proportional benefit: elevated IGF-1 promotes cellular proliferation indiscriminately, raising theoretical cancer risk in individuals with preexisting dysplastic lesions. The Framingham Heart Study Offspring Cohort found that IGF-1 levels in the highest quintile (>280 ng/mL in adults over 40) correlated with 1.6× increased incidence of colorectal adenomas over 10-year follow-up.

Monitor IGF-1 trend, not snapshot values. A single elevated or suppressed IGF-1 reading means little without context. If your baseline IGF-1 was 200 ng/mL, mid-cycle IGF-1 rises to 260 ng/mL, and 12-week post-cycle IGF-1 returns to 195 ng/mL. Your axis recovered. If 12-week post-cycle IGF-1 drops to 150 ng/mL, you've suppressed baseline production by 25%, which warrants intervention.

Comparison Table: Pre-Cycle vs Post-Cycle Lab Targets

What If: Ipamorelin Blood Work Scenarios

What If My Baseline IGF-1 Is Already High-Normal (>250 ng/mL)?

Don't start the cycle. If your baseline IGF-1 sits in the upper quartile of age-adjusted normal, your endogenous GH production is already robust. Adding exogenous secretagogues offers minimal incremental benefit and disproportionately increases suppression risk. The dose-response curve for growth hormone flattens above the 70th percentile; pushing IGF-1 from 250 to 280 ng/mL doesn't meaningfully improve body composition, recovery, or metabolic markers. Instead, address lifestyle factors that may be suppressing GH pulse amplitude. Chronic sleep restriction, high cortisol from overtraining, or insulin resistance all blunt natural GH secretion. Optimize those variables first; retest IGF-1 in 8–12 weeks and reassess.

What If My 12-Week Post-Cycle IGF-1 Is Still Suppressed Below Baseline?

Consult an endocrinologist immediately. IGF-1 remaining 15–25% below baseline at 12 weeks post-cycle indicates your hypothalamus has not restored endogenous GHRH pulsatility. This isn't temporary rebound suppression, it's durable dysfunction. Your physician will likely order a glucagon stimulation test or insulin tolerance test to measure peak GH secretion directly and confirm whether you've developed acquired growth hormone deficiency. Treatment typically involves low-dose GH replacement (0.2–0.4 mg subcutaneous daily) for 12–24 weeks to 'restart' the axis, tapering as endogenous secretion recovers. Do not attempt another peptide cycle while suppressed. Compounding the problem will only deepen axis shutdown.

What If My Fasting Glucose Rises Post-Cycle and Stays Elevated?

Address insulin sensitivity before considering another cycle. Growth hormone's counter-regulatory effect on insulin. Promoting hepatic glucose output and reducing peripheral glucose uptake. Can unmask latent insulin resistance. If your fasting glucose rises from 85 mg/dL pre-cycle to 105 mg/dL at 12 weeks post-cycle and remains elevated, you've shifted toward prediabetes. First-line intervention: reduce carbohydrate intake to <100g daily, prioritize resistance training 3–4× weekly, and retest glucose and HbA1c in 8 weeks. If glucose remains >100 mg/dL despite dietary changes, your physician may prescribe metformin (500–1000 mg daily) to restore insulin sensitivity before attempting another GH-elevating protocol.

The Uncomfortable Truth About Ipamorelin Blood Work

Here's the honest answer: most people using ipamorelin never run baseline labs, never retest post-cycle, and have no idea whether they suppressed their natural GH production. They rely on subjective markers. 'I feel better,' 'I'm leaner,' 'I recover faster'. And assume those sensations mean the peptide worked without harm. That's not how endocrinology works. Your hypothalamus doesn't care how you feel. It responds to negative feedback signals, and if you artificially elevate GH pulses for 12 weeks, it will downregulate GHRH output to compensate. Whether that downregulation is temporary or permanent depends on dose, duration, individual receptor sensitivity, and baseline axis function. Variables you can't assess without lab work.

The peptide research community treats lab work as optional. It's not. If you're unwilling to spend $150–250 on baseline and post-cycle panels, you're not ready to inject a compound that alters your pituitary axis. That's not gatekeeping. It's acknowledging that peptides aren't supplements. They're bioactive molecules with real endocrine consequences. Running ipamorelin without labs is like flying a plane without instruments. You might land safely. You might not. And you won't know which until it's too late.

Suppression isn't theoretical. Published case studies document individuals who developed persistent GH deficiency after peptide protocols, requiring years of replacement therapy to restore baseline function. That outcome is rare. Maybe 5–8% of users. But it's not zero. The only way to know if you're in that minority is to measure before, during, and after. If that sounds excessive, consider the alternative: discovering at age 50 that your IGF-1 sits at 90 ng/mL because you suppressed your axis at 35 and never recovered.

Why Standard 'Hormone Panel' Orders Miss Critical Markers

Most direct-to-consumer lab companies offer generic 'hormone optimization panels' that include testosterone, estradiol, cortisol, and sometimes DHEA-S. Those panels are designed for TRT (testosterone replacement therapy) monitoring, not growth hormone secretagogue evaluation. They won't include IGF-1 unless you specifically request it, and they rarely stratify results by age and sex. Rendering the numbers clinically meaningless.

IGF-1 assays also vary between labs. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard, offering ±5% coefficient of variation. Older immunoassay methods. Still used by some budget labs. Show ±15–20% variance, meaning your 'baseline' of 200 ng/mL could actually be anywhere from 160–240 ng/mL. If you're tracking axis recovery with that level of imprecision, you can't distinguish true suppression from assay noise. Use the same lab for all draws, preferably one that specifies LC-MS/MS methodology for IGF-1 measurement.

Timing matters for thyroid panels. TSH fluctuates diurnally, peaking between 2–4 AM and reaching its nadir around 2–4 PM. If you draw baseline TSH at 8 AM and post-cycle TSH at 3 PM, you're comparing different physiological states. Not actual axis changes. Standardize draw times to early morning (7–9 AM, fasting) for all thyroid and metabolic markers. Free T3 and free T4 are less time-sensitive but should still be drawn fasting to eliminate postprandial interference.

Our experience working with researchers across peptide protocols has shown one consistent pattern: the individuals who run complete pre-cycle labs, retest at structured intervals, and interpret results in context rarely experience durable suppression. The ones who skip labs, chase subjective gains, and assume 'feeling good' equals hormonal health are the ones who show up 18 months later with IGF-1 at 110 ng/mL and no clear path to recovery. Lab work isn't a formality. It's the difference between informed optimization and reckless experimentation.

If the cost of comprehensive panels feels prohibitive, Real Peptides offers research-grade compounds with exact amino-acid sequencing. Guaranteeing purity and consistency so your results aren't confounded by contaminated or underdosed product. The lab work investment protects the peptide investment. Both matter equally.